Barinthus Biotherapeutics (BRNS) Accumulated Depreciation & Amortization (2020 - 2024)
Historic Accumulated Depreciation & Amortization for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q4 2024 value amounting to $5.8 million.
- Barinthus Biotherapeutics' Accumulated Depreciation & Amortization rose 683.37% to $5.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.8 million, marking a year-over-year increase of 683.37%. This contributed to the annual value of $5.8 million for FY2024, which is 683.37% up from last year.
- As of Q4 2024, Barinthus Biotherapeutics' Accumulated Depreciation & Amortization stood at $5.8 million, which was up 683.37% from $5.4 million recorded in Q4 2023.
- In the past 5 years, Barinthus Biotherapeutics' Accumulated Depreciation & Amortization ranged from a high of $5.8 million in Q4 2024 and a low of $479000.0 during Q4 2020
- In the last 5 years, Barinthus Biotherapeutics' Accumulated Depreciation & Amortization had a median value of $4.3 million in 2022 and averaged $3.4 million.
- In the last 5 years, Barinthus Biotherapeutics' Accumulated Depreciation & Amortization soared by 38792.33% in 2022 and then soared by 683.37% in 2024.
- Quarter analysis of 5 years shows Barinthus Biotherapeutics' Accumulated Depreciation & Amortization stood at $479000.0 in 2020, then soared by 84.97% to $886000.0 in 2021, then surged by 387.92% to $4.3 million in 2022, then grew by 25.58% to $5.4 million in 2023, then grew by 6.83% to $5.8 million in 2024.
- Its last three reported values are $5.8 million in Q4 2024, $5.4 million for Q4 2023, and $4.3 million during Q4 2022.